CA2451725C - Therapeutic combinations for the treatment of hormone deficiencies - Google Patents

Therapeutic combinations for the treatment of hormone deficiencies Download PDF

Info

Publication number
CA2451725C
CA2451725C CA002451725A CA2451725A CA2451725C CA 2451725 C CA2451725 C CA 2451725C CA 002451725 A CA002451725 A CA 002451725A CA 2451725 A CA2451725 A CA 2451725A CA 2451725 C CA2451725 C CA 2451725C
Authority
CA
Canada
Prior art keywords
testosterone
estradiol
methyltestosterone
gel
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002451725A
Other languages
English (en)
French (fr)
Other versions
CA2451725A1 (en
Inventor
Roland Gerritsen Van Der Hoop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Products LLC
Original Assignee
Solvay Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Inc filed Critical Solvay Pharmaceuticals Inc
Priority to CA002501846A priority Critical patent/CA2501846A1/en
Publication of CA2451725A1 publication Critical patent/CA2451725A1/en
Application granted granted Critical
Publication of CA2451725C publication Critical patent/CA2451725C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002451725A 2001-06-27 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies Expired - Lifetime CA2451725C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002501846A CA2501846A1 (en) 2002-06-26 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/892,981 US20030027804A1 (en) 2001-06-27 2001-06-27 Therapeutic combinations for the treatment of hormone deficiencies
US09/892,981 2001-06-27
PCT/US2002/020141 WO2003002123A2 (en) 2001-06-27 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002501846A Division CA2501846A1 (en) 2002-06-26 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies

Publications (2)

Publication Number Publication Date
CA2451725A1 CA2451725A1 (en) 2003-01-09
CA2451725C true CA2451725C (en) 2006-12-12

Family

ID=25400826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451725A Expired - Lifetime CA2451725C (en) 2001-06-27 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies

Country Status (5)

Country Link
US (1) US20030027804A1 (enExample)
EP (1) EP1404343A4 (enExample)
JP (1) JP2005515964A (enExample)
CA (1) CA2451725C (enExample)
WO (1) WO2003002123A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466138B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
AR036970A1 (es) * 2002-03-15 2004-10-20 Unimed Pharmaceuticals Inc Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
EP1750766B1 (en) * 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2008517952A (ja) * 2004-11-01 2008-05-29 アンドルシェルシュ・インコーポレイテッド 皮膚老化となる可能性を低下させるための、または皮膚老化を処置するためのアンドロゲンの使用
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2044943A1 (en) * 2007-10-04 2009-04-08 Solvay Pharmaceuticals, Inc. Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
GB2482868A (en) * 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
CA2818491A1 (en) 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
JP6121990B2 (ja) 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
US9855281B2 (en) * 2013-11-20 2018-01-02 Scott Freeman Consultant, Llc Libido-enhancing therapeutic and use
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) * 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
BR0113649A (pt) * 2000-08-30 2004-07-20 Unimed Pharmaceuticals Inc Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US8466138B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466136B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466137B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8486925B2 (en) 2005-10-12 2013-07-16 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8729057B2 (en) 2005-10-12 2014-05-20 Unimed Pharmaeuticals, LLC Testosterone gel and method of use
US8741881B2 (en) 2005-10-12 2014-06-03 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8754070B2 (en) 2005-10-12 2014-06-17 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8759329B2 (en) 2005-10-12 2014-06-24 Unimed Pharmaceuticals, Llc Testosterone gel and method of use

Also Published As

Publication number Publication date
US20030027804A1 (en) 2003-02-06
WO2003002123A2 (en) 2003-01-09
JP2005515964A (ja) 2005-06-02
WO2003002123A3 (en) 2003-02-27
CA2451725A1 (en) 2003-01-09
EP1404343A2 (en) 2004-04-07
EP1404343A4 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
CA2451725C (en) Therapeutic combinations for the treatment of hormone deficiencies
EP1315502B1 (en) Method for treating erectile dysfunction and increasing libido in men
CA2419573C (en) Method of increasing testosterone and related steroid concentrations in women
US20050049233A1 (en) Method for treating erectile dysfunction and increasing libido in men
US20150250801A1 (en) Androgen pharmaceutical composition and method for treating depression
US20050152956A1 (en) Method of increasing testosterone and related steroid concentrations in women
US20070154533A1 (en) Method of increasing testosterone and related steriod concentrations in women
US20110306582A1 (en) Androgen pharmaceutical composition and method for treating depression
AU2003228314A1 (en) Androgen pharmaceutical composition and method for treating depression
CA2501846A1 (en) Therapeutic combinations for the treatment of hormone deficiencies
RU2286787C2 (ru) Способ повышения концентрации тестостерона и родственных стероидов у женщин
HK1115537B (en) A use of hydroalcoholic gel in the manufacture of medicine
HK1082677B (en) Androgen pharmaceutical composition and use for manufacture of medicament

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220627